BM-1197

BM-1197 (UBX1967) is a potent and selective inhibitor of dual Bcl-2/Bcl-xL, with IC50s of 3.5 nM and 5.2 nM for Bcl-2 and Bcl-xL, respectively. BM-1197 exhibits antitumor effects both in vitro and in vivo[1][2].

Product Specifications

CAS Number

[1391107-89-3]

Product Name Alternative

UBX1967

UNSPSC

12352005

Target

Bcl-2 Family

Type

Reference compound

Related Pathways

Apoptosis

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/bm-1197.html

Purity

99.48

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

C[S](=O)(C(C(C1=CC(N2CCN(C(C=C3)=CC=C3N[S](=O)(C(C=C4)=CC([S](C(F)(F)F)(=O)=O)=C4N[C@@H](CSC5=CC=CC=C5)CCN(CC6)CCC6O)=O)CC2)=CC(F)=C1)=C(C(C=C7)=CC=C7Cl)N8C(C)C)=C8C)=O

Molecular Formula

C53H59ClF4N6O7S4

Molecular Weight

1131.78

References & Citations

[1]Bai L, et, al. BM-1197: a novel and specific Bcl-2/Bcl-xL inhibitor inducing complete and long-lasting tumor regression in vivo. PLoS One. 2014 Jun 5; 9 (6) : e99404.|[2]Sun YL, et, al. A novel Bcl-2 inhibitor, BM-1197, induces apoptosis in malignant lymphoma cells through the endogenous apoptotic pathway. BMC Cancer. 2019 Dec 31; 20 (1) :1.